Pfenex Expression Technology: Microbial Expression Technology

Try the Next Generation in Microbial Expression Technology.
Pfenex Expression Technology™, a Pseudomonas-based system, enables customers to express their recombinant protein or peptide reliably and cost-effectively.

This technology can:

• Increase protein expression
• Secrete proteins to the periplasmic space
• Maintain solubility
• Increase downstream yield
• Scale up easily
• Address protease issues
• Improve activity characteristics
• Lower cost of goods

In developing Pfenex Expression Technology, Dowpharma continues to invest a significant amount of research and development in identifying high-performing strains of Pseudomonas fluorescens and further improving them through the application of sophisticated genomics tools. Dowpharma can quickly modify expression strains to increase the yield of a customer's biotherapeutic. Pfenex Expression Technology can help overcome some of the limitations of other bacterial expression systems, like disulfide bond formation, protease degradation of product and product secretion to the cellular periplasmic space to give you the highest possible product yield out of a microbial expression system.

A Scaleable Solution for your Peptide
If your therapeutic is a long peptide of more than 20 amino acids, requiring more than one kilo per year at commercial scale, Pfenex Expression Technology can provide you with a cost-effective alternative to traditional synthetic methods. If you have been satisfying your current clinical needs with solid phase synthesized material, it's time to think about what the best manufacturing alternative for the long term could be. Pfenex Expression Technology could be that alternative.

Developed to Meet Regulatory Requirements
Pfenex Expression Technology has been developed with regulatory requirements in mind, specifically eliminating the need for antibiotics for plasmid stability, while also avoiding animal-derived products using a defined medium. By improving expression and meeting regulatory expectations while reducing costs, we can help our customers increase the number of products that are commercially viable and which ultimately go to market.

In developing Pfenex Expression Technology, DowpharmaSM continues to invest a significant amount of research and development in identifying high-performing strains of Pseudomonas fluorescens, gene mapping these strains and improving them by application of sophisticated genomic tools. Dowpharma can quickly and easily modify the strains to increase the expression of a particular customer's biotherapeutic.

Options for Working with Pfenex Expression Technology
Dowpharma offers you a variety of ways to take advantage of this powerful technology:

• Initial feasibility study
• Process Development
• Pre-clinical and clinical manufacturing
• Pfenex Expression Technology out-licensing